Product Details:

CasNo： 2222844-89-3

Molecular Formula： C24H28F4N6

Appearance： Off white to yellowish solid

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

Camizestrant（AZD‑9833）

CAS：2222844‑89‑3

Brand name：ETCAMAH®European M...

Drug class：Next‑generation oral SERD (Selective Estrogen Receptor Degrader), complete ER‑α antagonist Developer：AstraZeneca

✅ Official Indication（ EMA / PMDA）

Camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) is indicated for the treatment of adult patients with ER‑positive, HER2‑negative locally advanced or metastatic breast cancer, upon detection of emergent ESR1 mutation while receiving first‑line endocrine therapy plus CDK4/6 inhibitor, in the absence of radiographic disease progression.

 

中文释义： Camizestrant 联合 CDK4/6 抑制剂（哌柏西利、瑞博西利、阿贝西利），用于成人 ER 阳性、HER2‑阴性局部晚期或转移性乳腺癌；患者在一线内分泌 + CDK4/6 抑制剂治疗期间，检出新发 ESR1 突变、尚未出现影像学疾病进展时使用European M...。

Approval timeline：Japan PMDA approved Jun‑2026; EU CHMP positive opinion May‑2026; US FDA accelerated approval Sep‑04‑2026。

 

📄 Product English Description

Camizestrant (AZD‑9833) is a potent, next‑generation, orally bioavailable selective estrogen receptor degrader (SERD) and full ER‑α antagonist. It binds to both wild‑type and ESR1‑mutated estrogen receptor‑α, induces proteasome‑mediated receptor degradation, and suppresses ER‑dependent gene transcription, thereby inhibiting proliferation of ER‑positive breast cancer tumor cells, including endocrine‑resistant clones driven by ESR1 activating mutations. Unlike fulvestrant (injectable SERD), camizestrant is administered orally once‑daily. It is clinically evaluated both as monotherapy and in combination with CDK4/6 inhibitors for HR‑positive, HER2‑negative advanced breast cancer. The recommended clinical dose is 75 mg once daily. Therapy shall be continued until disease progression or unacceptable toxicity occurs.

Safety brief note

Common adverse events include hot flush, nausea, fatigue, musculoskeletal pain. Not recommended during pregnancy and lactation. Effective contraception is required for patients of reproductive potential.